Experience of human normal immunoglobulin (Privigen, CSL BEHRING) administration in patients with Guillain - Barre syndrome in non-specialized neurological department

Abstract

Objective - to assess the own experience of human normal immunoglobulin (Privigen, CSL Behring) administration in patients with Guillain - Barre syndrome. Material and methods. Clinical cases of patients with Guillain - Barre syndrome treated with human normal immunoglobulin (Privigen) in 2016-2017. Guillain - Barre syndrome corresponded to the disease clinical and diagnostic criteria. Efficiency of this treatment was considered by improvement of motor and pelvic functions. Besides, side effects and tolerability were assessed clinically. Results. 3 GBS patients underwent treatment. There was improvement of varying degrees in 3 cases, which included improvement in motor sphere and improvement in urination. One case was fatal because of pulmonary and cardiac failure caused by pneumonia. Expected slight side effect was in 1 case, which includes nasopharyngitis, was treated in within days. Conclusion. Results of implementation of human normal immunoglobulin (Privigen, CSL Behring) were ambiguous.

Keywords

• guillain - barre syndrome
• privigen
• immunoglobulins